Lead author Jeffrey Lazarus and co-author Jörn Schattenberg join Stephen Harrison, Louise Campbell and Roger Green to discuss the groundbreaking paper “Advancing the Global Health Agenda for NAFLD.” In this conversation, Jeff discusses how the study was executed, Jörn describes his role and Stephen Harrison comments from a physician’s perspective.
The Surfers convene to discuss “Advancing the Public Health Agenda for NASH,” a paper recently published in Nature Reviews Gastroenterology and Hepatology, with lead author Jeffrey Lazarus and co-author Jörn Schattenberg.
This episode focuses on the importance of NASH cirrhosis clinical trials. The conversation summarizes the status of four ongoing trials and addresses issues of disease naming and the value of incorporating MRE into trial designs.
Jörn Schattenberg and Mazen Noureddin join the Surfers to discuss five recently-reported or ongoing clinical trials in NASH cirrhosis.
Manal Abdelmalek, Jörn Schattenberg and Ian Rowe join regulars Stephen Harrison, Louise Campbell and Roger Green to recap NAFLD and NASH-related insights from TLMdX 2021, the AASLD annual liver meeting. This conversation focuses on, in the words of Stephen Harrison, “putting a big, fat dent in Fatty Liver disease.”
Manal Abdelmalek, Jörn Schattenberg and Ian Rowe join regulars Stephen Harrison, Louise Campbell and Roger Green to recap this week’s just-concluded the AASDL 2021 TLMdX annual liver meeting.
Drs. Michael Charlton and Mazen Noureddin and Global Liver Institute Director of Global NASH Programs Jeff McIntyre join Dr. Stephen Harrison, Louise Campbell and Roger Green to review some of the most important and exciting presentations from the final two days of the 2021 TLMdX, the annual meeting of AASLD
Profs. Scott Friedman and Michelle Long, Dr. Naim Alkhouri and Global Liver Institute DIrector of Global NASH Programs Jeff McIntyre join Louise Campbell and Roger Green to review some of the most important and exciting presentations from the first three days of the 2021 TLMdX, the annual meeting from AASLD.
Global Liver Institute Founder, President and CEO Donna Cryer and her fellow patient and patient advocate Terri Milton join Stephen Harrison, Louise Campbell and Roger Green. They discussed the ground-breaking NASH Patient-Focused Drug Development meeting held on November 4, 2021. This included the advocates’ priorities (both those who spoke in the PFDD session and others like our panelists) for changes in regulatory policy and programs.
Global Liver Institute Founder, President and CEO Donna Cryer and her fellow patient and patient advocate Terri Milton join Stephen Harrison, Louise Campbell and Roger Green to discuss the ground-breaking NASH Patient-Focused Drug Development meeting held on November 4, 2021 and the advocates’ perspectives that individuals brought to the meeting.
